39 3 Vol.39NO.3 2019 03 JOURNALOFGANNANMEDICALUNIVERSITY MAR.2019 86"34 1, # 1, 2, 1,V 2,G 2 ( 1.2016;2.$<U, 341000) " #:U[\]%3_`a a(]%,uk(,? SB9\('5,1N(,S(-C8 JKS8U[\]%(S,S(\2S\&'U[\] %(,S-(8 -SU[\]%&(= U[\]%&(6 :S;U[\]% ()*+:R730.2,-./0:A,1+:1001-5779(2019)03-0309-05 DOI:10.3969/j.isn.1001-5779.2019.03.024 Recentadvancesinautophagyandgynecologicalmalignanttumors LAIFengdi 1,XULing 1,YEPing 2,KANGChuanchuan 1,XIEXiaoying 2,WANGMaohuai 2 (GannanMedicalUiniversity1.Postgraduatestudents,Grade2016;2.TheFirstAfilaitedHospital,Ganzhou,Jiangxi341000) Abstract:Gynecologicalmalignanttumorisakindoftumorwithhighmorbidityandmortality,whichposesagreatthreat towomen'shealth.autophagyisalysosomaldependentproteinmetabolicbalanceproces,andalsoparticipatesinthe maintenanceofstableinternalenvironment.astheresearchersofautophagyandthefurtherresearchofgynecologicmalig nanttumors,autophagyactivitychangeandautophagicceldeathiscloselyrelatedtothedevelopmentofgynecologicma lignanttumors,autophagyisexpectedtobecomethenewtargetforcancertherapy.thispaperreviewstherecentprogres ofautophagyingynecologicalmalignanttumorsanditsapplicationindiagnosisandtreatmentofgynecologicalmalignant tumors. Keywords:autophagy;Gynecologicalmalignanttumor U[\]%IU(] %,JK MN H O S-?(,5, &'/,(&' ('8 \AB(,IR382.& ' 5,JKX Xb X 8, &'( [1] -SU [\]%(= 1 8< S\F,NK (H*JLTB,,AC(&'N(5 1962,Ashford8 Porten6 (&'&_&'S JKS (mi croautophagy) S (macroautophagy)8, ( S (chaperonemediatedautophagy, CMA) SOZ4M(S ] % VG3\` =HR3 `5&S [2] ^I,]%&'&',2(S \( 2 86 @-&'(4,S45]% 23:,,,0,:U]% Email:451907834@qq.com :,,,,,:U]% Email:xiexiaoying603@126.com 309
2019 &'('8C(&' B,>?&'/, I>?+(_ S]%(>?@6D F:1 C(&',;2Sc&'(, _,S Atg78 Beclin1( RNA, CKD Caspase>?Z zvad(! L929 &'(;3>?9+,I8DH#(0 N\,_SC=]%&'( DF:1Katheder A_]%45LX(,6X(,45S=] %&'(S< [3],-3+C_ 3HI;2SX&b- (vascularendothelialgrowthfactor,vegf) (D,VEGF5NCXS(\,`1 =]%&'-(8 -&' (4\(L,I=]%( [4] ; 3S(]%&'JNCD= ]%(;43,S45K D,]% (5&, &'S(@6E\ U + _ ( S ' J K Beclin18-' 3(LC3) Beclin1 E-S(Atg)6',P4 S&&@6,^S( C [5],Beclin1(FXJ!X(,IXJ Beclin1S_]%,Beclin10(]%>?' [6] LC3 (LC3Ⅰ)8H*F(LC3Ⅱ), S ( H S \ LC3ⅡT-S(?( [7] U + ( S ( c PI3K/AKT/ mtorc,lkb1/ampkc8 Ras/Raf/ERKc [8],&'(C8X (/4&' N8,7,CYS Ⅱ&' 3(&'Ⅰ \&'8&'(01DF :S&'(0_ DNA18 (,^023_ [9]?&',S8&'T,85 O;>?L5 [10] S]%_&(@6+() 310 *8:9( U +(:FS 3 86 Pb,\(+, _ & [ \ + ( & [10-11],70% ( % ` (HPV)168 18(=HH [12],MNM( S2&(&'8, (@6(8 Beclin1/ //(D _ Beclin1( 8(/(D/ C\[\/&(DG,G [13] - Beclin1(XD) *^84:=(R5 *AVKUS\C](I,(&' 8)]&A(/B& HPV=H8 J 3A (ATAD3A)( S ATPase[ \ AAAZD(,_( HPV=H8 ATAD3A(DL. [14] _ ATAD3AD FIGO * 6 9+8(&'8]Q,\ HPV=HL ATAD3A( D,S]%>?(&J *A VSCD((&',3 ] %_8+&@6 J(80?(( _,8.\ [15-16] &'2& '58L&'(DD(CD,X =CS@-[\]%(28 DO,/'734B>?Z(histone deacetylaseinhibitor)45 Beclin1(D8>?'BS,I>?]%( [17] 6/ HeLa&'I,&'S\ 8&'OL,I^ Beclin1O,UV />?&' &'S\ &'?C Beclin1(D + Beclin1NH>I_, S Beclin1OLX3(&',IX(&'\@6 S Beclin1-(8
3, SU[\]%(= 4 86B _[,H(U [\]% [18]?N+), 2017 61380(+`TN, 10920 UH [19] SW,I^WSH(,-+( ⅠHD PI3K/Akt/ mtorcn=/8 c(fa KA7$(mTOR),/S(>?Z, CY(S [20] HIF,Y( X8Q2 PI3K/Akt/mTOR4 (3,8DS(,ⅠH,4(=&'8,UV3 (+5SC=]%(_ Sivridis LC3HB R HB,80(H8 HB&(D [21] LC3 (E- @ *(SLS),T-5S (,8*+(]%( \ GLM,H&( SLS 8(/,/(SS 5a,SLSR H-&(IR,K SLS (LC4 1HBR \H(K$ 1 /HBB-& Beclin1(D8F [21] Beclin1DM, ]%,M SM 5 am, Beclin1DX,DO LSC]%X&( V Beclin1(FCHB 2(_,L\SH &(@6 [22] SH7(bCJK $121(EIG121) EIG121& ' H ( P H ' 8 S ' [23] EIG121(H&5D,I09 $(H&(D>? A,EIG121XcQ(DFS 8&',V EIG121CH( =&'( ^,S(,Beclin1 LC38 EIG121(,H(=80I DO X8XTcQ(HIF,S@-&'(? 5 86CD _&[,MNU[\]%( _,SMN (_ _&(P# 40% ~75% (MN]- Beclin1(XJ p53 60% ~80%(_\8[\\MN&2 8XJ 27% (MN& PTEN(J [24],S' PEA15A2 ;&'&(',>?MN&'(, _ PEA15D(]^a PEA 15D(],-=MN^I( *ADOS(XJ8 FMN8= 5N,(*ADO>?SC LMN&'( Smith 3 R(As 2 O 3 ) Hey SKOV33MN&' T80(>?@6&,-SC2.MN& ' [25],Ⅰ8ⅡO&'MN,Ⅲ O&'MN& LC3ASLS *A WL3(MN&,VS [\]%(01&_M01(@6 ARHI@-&'( GTPB>?Z [26], 5 60%(MNDF [27],MN BV ARHIC>?MN&' 8- [28]!&@-6 (MN&'& ARHI(,,X8XcQ,S X [29] 5.1 8bCDN )S@-MN(D (?S@-]%Z8]%>? (ST@6,DO,SZ8>?Z KI&'48/F LeV2U,FDA B( \&'\'`(,45MN& ' Hey8 SKOV3(SN>?MN&'( (,LCYOS>? (?I0(2U(A(& '8 *ADO2UMN&'(@ 6LS 311
2019-3.\(_MN&( [,MN&'86&, F(6E(1@6,_S)*1 @6(? [30] Chen45MN& '48F(6LL 3Z8 4VWA (SAHA) / ' 7 3 4 B ( @ 6 [31],_L SAHAX HEY&'&LL (S,CLS\b ARHI (D,>? ARHICLLS(@6, 0)*LL8 SAHA(>?@6 VF(6 Rad001,A7$( (S(Z)8 3R(S( 3Z),CMN&'&>?(1@6,5&S8&', C>? PI3K/AKT/mTORc 6 ' S=35&2&'& &'N(&'5 +DSU[\] %,GOS]% &(@6@ -XZ(D (*ADOS +&M@6,@6/8: (01I (_& S(F,IS(H MN&,-DO>?S[\] %(_8=)*,LDOS =MND8X&( HIF,S`>?]%_,I LHIF,S8XcQF(,S383.\(_&@ 6 P#43(+801, XS+&(@6(25)Y (7 -O(S@6U[\]%( _`?&,8=>N O3+(& GLS U[\]%&P#UQ8,) _`a8u 5a [\,-: [1] OzpolatB,BenbrookDM.Targetingautophagyincancer managementstrategiesand developments[j]. Cancer ManagRes,2015,7:291-9. [2] MizushimaN,LevineB,CuervoAM,etal.Autophagy fightsdiseasethroughcelularselfdigestion[j].nature, 2008,451(7182):1069-1075. [3] KathederNS,KhezriR,O'FarelF,etal.Microenvir onmentalautophagypromotestumourgrowth[j].nature, 2017,541(7637):417-420. [4],,YY,.S]%( =[J].,2018,38(3):260-264. [5] EskelinenEL,SaftigP.Autophagy:alysosomaldegrada tionpathwaywithacentralroleinhealthanddisease[j]. BiochimBiophysActa,2009,1793:664-73. [6] YueZ,JinS,YangC,etal.Beclin1,anautophagy geneesentialforearlyembryonicdevelopment,isahap loinsuficienttumorsuppresor[j].procnatlacadsci USA,2003,100:15077-82. [7] KlionskyDJ,AbdalaFC,AbeliovichH,etal.Guide linesfortheuseandinterpretationofasaysformonito ringautophagy[j].autophagy,2012,8:445-544. [8] ZhouS,ZhaoL,KuangM,etal.Autophagyintumori genesisand10.cancertherapy:dr.jekylormr[j]. HydeCancerLet,2012,323:115-27. [9] GozuacikD,KimchiA.Autophagyandceldeath[J]. CurTopDevBiol,2007,78:217-45. [10] ChauhanS,JaggiM,BelM,etal.Epidemiologyof humanpapilomavirusincervicalmucosa[j].methods MolBiol,2009,471:439-56. [11] EinsteinMH,SchilerJT,ViscidiRP,etal.Clinician's guidetohumanpapilomavirusimmunology:knownsand unknowns[j].lancetinfectdis,2009,9:347-56. [12] IbeanuOA.Molecularpathogenesisofcervicalcancer [J].CancerBiolTher,2011,11:295-306. [13] ChengHY,ZhangYN,WuQL,etal.Expresionof beclin1,anautophagyrelatedprotein,inhumancervi calcarcinomaanditsclinicalsignificance[j].eurj GynaecolOncol,2012,33:15-20. [14] OrfaneliT,JeongJM,DoulaverisG,etal.Involve mentofautophagyincervical,endometrialandovarian cancer[j].internationaljournalofcancerjournalin ternationalducancer,2013,135(3):519. [15] RosaDD,MedeirosLR,EdelweisMI,etal.Adjuvant platinumbasedchemotherapyforearlystagecervicalcanc er[j].cochranedatabasesystrev,2012,6:cd005342. [16] YeeGP,deSouzaP,KhachigianLM.Curentandpo tentialtreatmentsforcervicalcancer[j].curcancer DrugTargets,2013,13:205-20. [17],,N].U[\]%&S( =[J].U,2017,44(1):5-8. ( 316) 312
2019 -I [\,-: [1].M:ZF (-[J]. (),2014,12(2):26-28. [2] X,,8,.( \, -[J].J-,2017,33(23):3295-3299. [3].(J-A[J].,2007, (3):42. [4] ].Y 4 C J - - [J].,2018,32(9):33-38. [5],,.(CY4 J-C,D[J].&--,2017,34(1):56-57+64. [6] N,,.F J-()*$[J].,2017,30 (5):80-82. [7] %,9.(( D:P[J].&--,2017,34(6):407-408+422. [8] T,,O.J-$ _[J].,2017,37(5):711-713. [9],.,.)*(CJ -1 = ( $ Q [J]. @,2016,30 (3):172-176. (,:2018-08-09)( :"# ) ( 312) [18] FastStats.AninteractivetoolforaccestoSEERcancersta tistics[c].surveilanceresearchprogram,nationalcancer Institute.2011,Availableat:htp://seer.cancer.gov/fast stats. [19] SiegelRL,MilerKD,JemalA.CancerStatistics,2017 [J].CACANCERJCLIN,2017,67:7-30. [20] DongP,KaneuchiM,KonnoY,etal.Emergingthera peuticbiomarkersinendometrialcancer[j].biomed ResInt,2013,2013:130362. [21] KoutsopoulosA,KoukourakisM,KoutsopoulosA,et al.highbeclin1expresiondefinesapoorprognosisin endometrialadenocarcinomas[j]. Gynecol Oncol, 2011,123:147-51. [22] haojh,wanxy,xiex,etal.expresionandclinical significanceofbeclin1andpteninendometrialcarcino ma[j].aizheng,2006,25:753-7. [23] DengL,BroaddusRR,McCampbelA,etal.Identifica tionofanovelestrogenregulatedgene,eig121,induced byhormonereplacementtherapyanddiferentialyex presedintypeiandypeiendometrialcancer[j].clin CancerRes,2005,11:8258-64. [24] OrfaneliT,JeongJM,DoulaverisG,etal.Involve mentofautophagyincervical,endometrialandovarian cancer[j].internationaljournalofcancerjournalinter nationalducancer,2013,135(3):519. [25] AletiGD,GostoutBS,PodratzKC,etal.Ovarian cancersurgicalresectability:relativeimpactofdisease, patientstatus,andsurgeon[j].gynecoloncol,2006, 100(1):33-37. [26] YuY,XuF,PengH,etal.NOEY2(ARHI),animprinted putativetumorsuppresorgeneinovarianandbreastcarcino mas[j].procnatlacadsciusa,1999,96:214-9. [27] RosenDG,WangL,JainAN,etal.Expresionofthe tumorsuppresorgenearhiinepithelialovariancancer isasociatedwithincreasedexpresionofp21waf1/ CIP1andprolongedprogresionfreesurvival[J].Clin CancerRes,2004,10:6559-66. [28] BadgwelDB,LuZ,LeK,etal.Thetumorsuppresor genearhi(diras3) suppresesovariancancercel migrationthroughinhibitionofthestat3andfak/rho signalingpathways[j].oncogene,2012,31:68-79. [29] LuZ,LuoRZ,LuY,etal.ThetumorsuppresorgeneAR HIregulatesautophagyandtumordormancyinhumanovarian cancercels[j].jclininvest,2008,118:3917-29. [30] BastRCJr.Molecularapproachestopersonalizingman agementofovariancancer[j].annoncol,2011,22 (Suppl8):vi5-vi15. [31] ChenMY,LiaoWS,LuZ,etal.Decitabineandsuberoy lanilidehydroxamicacid(saha)inhibitgrowthofovarian cancercellinesandxenograftswhileinducingexpresion ofimprintedtumorsuppresorgenes,apoptosis,g2/m ar rest,andautophagy[j].cancer,2011,117:4424-38. (,:2018-06-22)( :"#) 316